Sign in
CompletedPhase 2

Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R+ Membranous Nephropathy (aMN) (NewPLACE)

Key facts

Who runs it
HI-Bio, A Biogen Company
Where
Georgia, Germany, Greece, Russia, South Korea, Taiwan, and United Kingdom25 sites in 7 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
24 people enrolled
Started
20 Jan 2021
Ended
14 Dec 2023
Type of study
Interventional, 2 groups
Treatments tested
  • MOR202
Record updated
7 February 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Subjects ≥ 18 to ≤ 80 years (at date of signing the informed consent form [ICF])
  • Urine protein to creatinine ratio (UPCR) of ≥ 3.0 g/g or proteinuria ≥ 3.5 g/24 h
  • Estimated glomerular filtration rate (eGFR) ≥ 50 ml/min/1.73 m² (eGFR >30 and < 50 ml/min/1.73 m² can be included provided an interstitial fibrosis and tubular atrophy (IFTA) score of < 25% in a kidney biopsy)
  • Not in spontaneous remission despite proper treatment with angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs) (sufficient dose and treatment duration) as per clinical practice and scientific guidelines. If the subject is intolerant to ACEI and ARBs, the reason must be documented and approval for enrollment be obtained from the Medical Monitor
  • Systolic blood pressure (BP) ≤150 mmHg and diastolic BP ≤100 mmHg after 5 minutes of rest
  • Serum anti-PLA2R antibodies ≥ 50.0 RU/mL determined by Euroimmun ELISA
  • Female subjects: A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:; Not a female of childbearing potential (FCBP); A FCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of MOR202

Who cannot take part

  • Hemoglobin < 80 g/L
  • Thrombocytopenia: Platelets < 100.0 x 10\^9/L
  • Neutropenia: Neutrophils < 1.5 x 10\^9/L
  • Leukopenia: Leukocytes < 3.0 x 10\^9/L
  • Hypogammaglobulinemia: Serum immunoglobulins ≤ 4.0 g/L; Subjects may receive supportive therapies to meet the above criteria
  • Diabetes mellitus type 2: Subjects with type 2 diabetes mellitus may only enter the clinical trial if a kidney biopsy performed within 6 months prior to screening shows MN without evidence of diabetic nephropathy and diabetes is controlled, as shown by:; Glycated hemoglobin (HbA1c) <8.0 % or 64 mmol/mol; No diabetic retinopathy known; No peripheral neuropathy known
  • Total bilirubin, aspartate aminotransferase or alanine aminotransferase >1.5 x ULN, alkaline phosphatase >3.0 x ULN
  • B-cells < 5 x 10\^6/L

This trial has no sites in United States.

It has sites in 7 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This 2-arm, multi-center, open-label, parallel-group phase II trial will assess the efficacy, safety and pharmacokinetics/pharmacodynamics of the human antibody MOR202 in subjects with anti-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy

The 2 groups in the trial

  • MOR202 5 DosesTreatment being tested

    5 doses administered on Day 1, 8, 15, 29, and 57

    Treatment: MOR202

  • MOR202 2 DosesTreatment being tested

    2 doses administered on Day 1 and 15

    Treatment: MOR202

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (NewPLACE)
Publications
Record updated
7 February 2025